Potential for CytoDyn’s PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA Apr 17, 2017 6:00am EDT
Reminder: CytoDyn to Hold Investment Community Conference Call April 18, 2017 Apr 13, 2017 4:10pm EDT
Data Presented at CROI Show CytoDyn’s Pro 140 as a Single Agent Provided Maximal Virologic Suppression in HIV Patients for Nearly Two Years Feb 15, 2017 7:00pm EST
Two-Year Update From CytoDyn’s PRO 140 Monotherapy Study in HIV to be Featured in Two Events at CROI 2017 Feb 14, 2017 6:30am EST
CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman Jan 30, 2017 6:30am EST
CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy Jan 11, 2017 6:30am EST
CytoDyn Reports Treatment of First Several Patients With PRO 140 in Its Phase 3 Monotherapy Trial for HIV Dec 12, 2016 6:00am EST
